Reading view
SaaS-Bench: Can Computer-Use Agents Leverage Real-World SaaS to Solve Professional Workflows?
Integrated single-cell and bulk RNA sequencing reveals novel biomarkers of invasive adenocarcinoma subtypes in lung adenocarcinoma
Transl Cancer Res. 2026 Apr 30;15(4):314. doi: 10.21037/tcr-2025-aw-2503. Epub 2026 Mar 20.
ABSTRACT
BACKGROUND: Lung adenocarcinoma (LUAD) is one of the most common lung cancer subtypes worldwide, and its aggressive subtype invasive adenocarcinoma (IAC) has low survival rates. The precise identification of IAC is vital for the clinical diagnosis and treatment. The purpose of this study is to identify novel biomarkers for LUAD using single-cell and bulk RNA sequencing, so as to provide theoretical basis and practical support for the diagnosis, treatment and prognosis evaluation of lung invasive adenocarcinoma.
METHODS: We employed a combination of transcriptomic analysis and single-cell analysis to investigate the molecular characteristics and immune microenvironment of four subtypes of LUAD, including atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and IAC, with the aim of screening for biomarkers to differentiate pre-invasive lesions from invasive lesions.
RESULTS: Transcriptomic and single-cell analyses revealed that IAC subtypes demonstrated the most substantial molecular differences, particularly in immune cell infiltration and immune-related gene expression. Three genes-CD27, TIGIT, and TNFRSF18-that were significantly upregulated in IAC, predominantly expressed in immune cells and closely linked to immune regulatory pathways. We further analyzed T cell subpopulations in the IAC subtype and explored the expression of transcription factors (TFs) corresponding to these three genes, revealing their critical roles in immune cell function. Additionally, communication between T cells and other cells showed significantly enhanced signaling pathways, particularly those related to immune co-stimulatory molecules and inflammation pathways. Immunohistochemical validation of clinical samples showed that these three genes have high diagnostic value in IAC subtypes. These findings establish a crucial biological foundation for diagnosis, classification, and immunotherapy of LUAD, which contributes to the development of individualized treatment strategies.
CONCLUSIONS: This study identifies a three-gene signature (CD27, TIGIT, and TNFRSF18) that not only distinguishes invasive from pre-invasive LUAD with high precision by capturing the immune checkpoint disequilibrium characteristic of IAC, but also provides a clinically actionable biomarker panel for preoperative diagnosis and personalized immunotherapy strategies.
PMID:42180871 | PMC:PMC13190665 | DOI:10.21037/tcr-2025-aw-2503
A pathogen lncRNA secreted into rice sequesters a host miRNA for virulence
Nature, Published online: 20 May 2026; doi:10.1038/s41586-026-10572-x
A fungal long non-coding RNA from Magnaporthe oryzae translocates into rice cells to sequester a host microRNA that normally represses PKR1, a negative immunity regulator, thereby facilitating infection and revealing a widespread RNA-based pathogen–host interaction mechanism.ATIC Promotes LIHC Progression and Serves as an Independent Prognostic Marker: A Pan-cancer Transcriptomic Analysis
Curr Mol Med. 2026 May 11. doi: 10.2174/0115665240438824260113042223. Online ahead of print.
ABSTRACT
BACKGROUND: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/ IMP cyclohydrolase(ATIC) is a 64-kDa bifunctional enzyme, 5-aminoimidazole- 4-carboxamide ribonucleotide formyltransferase (AICART) and IMP cyclohydrolase, respectively. catalyzes the last two steps of the purine ab initio biosynthetic pathway. ATIC has been implicated in cancer progression, but its pan-cancer profile and specific prognostic utility in liver hepatocellular carcinoma (LIHC) remain incompletely defined.
METHODS: We analyzed TCGA RNA-seq data across 33 tumor types to assess ATIC expression, diagnostic performance (ROC/AUC), and prognostic associations (OS, DSS, PFI). We correlated ATIC expression with immune infiltration, TMB, MSI, and predicted neoantigen load, and constructed a LIHC-specific prognostic nomogram integrating ATIC and clinicopathologic features. Enrichment analyses (STRING, GO/KEGG, GSEA) and pharmacogenomic correlations (GDSC, CTRP) were performed to explore mechanisms and drug sensitivities.
RESULTS: ATIC was significantly upregulated in 16 tumor types, including LIHC (p<0.001). Pan-cancer ROC analyses showed high diagnostic accuracy in several cancers (examples: CHOL AUC=1.000, LIHC AUC=0.936, LUAD AUC=0.947). High ATIC expression associated with poorer OS in ACC, HNSC, LIHC, and PAAD (eg, LIHC: HR=1.39(1.04-1.85), p=0.028). In LIHC, ATIC correlated with advanced T stage, higher grade, elevated AFP, and shorter OS. Multivariable Cox regression identified ATIC expression and pathological T stage as independent predictors; time-dependent ROC for the LIHC nomogram showed AUCs of 0.711, 0.649, and 0.653 at 1, 3, and 5 years, respectively. GSEA indicated enrichment of PI3K-AKT-mTOR, MYC targets, and cell-cycle pathways in ATIC-high LIHC. High ATIC expression correlated with predicted increased sensitivity to sorafenib, doxorubicin, cisplatin, epothilone, and mitomycin in the TCGA-LIHC cohort.
DISCUSSION: ATIC upregulation across cancers links to tumor progression, immune modulation, and prognosis (LIHC), suggesting oncogenic roles in pan-cancer contexts. TCGA multi-omics show ATIC associates with immune/molecular subtypes, MSI/TMB/neoantigens, and predicts drug sensitivity, indicating diagnostic/prognostic potential.
CONCLUSION: ATIC is broadly upregulated across cancers and functions as an independent prognostic biomarker in LIHC. The ATIC-integrated nomogram shows modest predictive accuracy for LIHC survival. Our results implicate ATIC in oncogenic signaling (PI3K-AKT-mTOR, MYC, and cell-cycle) and suggest ATIC as a candidate biomarker to guide targeted and chemotherapeutic strategies in LIHC. Further in vitro and in vivo validation is warranted.
PMID:42152649 | DOI:10.2174/0115665240438824260113042223
Chuanminshen violaceum (Apiaceae) as a medicinal-and-edible resource: phytochemical diversity, bioactivities, and routes to standardized products
J Ethnopharmacol. 2026 Apr 6:121628. doi: 10.1016/j.jep.2026.121628. Online ahead of print.
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Chuanminshen violaceum Sheh et Shan is a medicinal-and-edible Apiaceae plant in China recorded for yin nourishment, lung/spleen tonification, and phlegm resolution, and used for cough and chronic respiratory complaints.
STUDY AIM: To synthesize current evidence on botanical resources, chemistry, pharmacology, and applications of C. violaceum, and to define priorities for standardized and safe development.
MATERIALS AND METHODS: This review integrates studies on resource distribution and ecological adaptability, multi-fraction phytochemistry, extraction-purification and formulation technologies, preclinical pharmacology, and quality, safety, and regulatory considerations.
RESULTS: C. violaceum contains structurally diverse polysaccharides plus volatile oils (often polyacetylene-rich), phenolics (e.g., chlorogenic acid and rutin), PUFA-rich lipids, and newly reported minor constituents. Polysaccharides show variable monosaccharide profiles, molecular-weight ranges, and linkage/branching patterns, strongly influenced by extraction-purification; derivatization (e.g., sulfation/selenization) and delivery systems can further tune physicochemical properties. Preclinical studies report antioxidant, anti-inflammatory, immunomodulatory, cardioprotective, and antiviral effects, commonly linked to Nrf2/Keap1 redox defense, inflammatory signaling control, TLR2/4-related immune regulation, gut-barrier reinforcement with microbiota remodeling, and anti-ferroptotic protection in myocardial ischemia-reperfusion models. Applications span traditional dosage forms and functional foods, but translation is limited by origin/process variability, incomplete long-term safety and ADME data, and regulatory uncertainty.
CONCLUSIONS: C. violaceum is a promising ethnomedicinal resource with clear part-specific features and polysaccharide-centered potential. Future work should combine multi-omics with target validation, fingerprint-guided QC and traceability, greener scalable processing, and regulatory-aligned safety packages to enable reproducible products.
PMID:41951195 | DOI:10.1016/j.jep.2026.121628
Editing strigolactone hormone receptor for robust antiviral silencing in rice
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation
Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation